A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Allergic Rhinitis Clinical Trial

Official title:

A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01160861
• Other study ID #: MOP4840g
• Status: Completed
• Phase: Phase 1
• Start date: July 11, 2010
• Est. completion date: April 2011

Study information

• Verified date: December 2022
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase Ib, randomized, blinded, placebo-controlled, multiple-ascending dose study in patients with seasonal or perennial allergic rhinitis to investigate the safety, tolerability, and pharmacokinetics (PK) of MEMP1972A.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Diagnosis of allergic rhinitis

• In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs

• Males or females who are surgically sterilized, post menopausal for the past year, or are using two acceptable methods of contraception against pregnancy through at least 6 months after the dose of study drug

Exclusion Criteria:

• History or clinical manifestations of significant metabolic, hepatic, renal, hematologic, immunodeficiency, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders

• History of anaphylaxis, hypersensitivity or drug allergies

• Use of a non-biologic investigational drug or participation in an investigational study with a non-biologic drug within 30 days prior to dosing

• Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 3 months prior to dosing

• Positive blood test for chronic viral infections by: hepatitis B surface antigen, hepatitis C virus antibody, or HIV antibody

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis
• Rhinitis, Allergic

Intervention

Drug:
• MEMP1972A
Repeating ascending dose
• placebo
Repeating ascending dose

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and nature of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results		Throughout study or until early discontinuation
Primary	Incidence, nature, and severity of adverse events		Throughout study or until early discontinuation
Secondary	Pharmacokinetic parameters of MEMP1972A (maximum plasma concentration, total serum clearance, volume of distribution, half-life)		Throughout study or until early discontinuation